Want to learn more about joining us in research?

Institute for Neurodegenerative Disorders
Institute for Neurodegenerative Disorders
  • Home
  • About Us
    • The Institute
    • Leadership Team
  • Participate
    • How To Participate
    • Clinical Trials
    • Active Studies
  • Resources
    • Neurologic Conditions
    • Parkinson Disease
    • Alzheimer Disease
    • Huntington Disease
    • Brain Imaging
    • Imaging in Alzheimer
    • Imaging in Parkinson
    • General Resources
  • Contact Us
  • Directions
  • Donate
  • More
    • Home
    • About Us
      • The Institute
      • Leadership Team
    • Participate
      • How To Participate
      • Clinical Trials
      • Active Studies
    • Resources
      • Neurologic Conditions
      • Parkinson Disease
      • Alzheimer Disease
      • Huntington Disease
      • Brain Imaging
      • Imaging in Alzheimer
      • Imaging in Parkinson
      • General Resources
    • Contact Us
    • Directions
    • Donate
  • Home
  • About Us
  • Participate
  • Resources
  • Contact Us
  • Directions
  • Donate

Brain Imaging

The development of innovative imaging techniques is a key feature of the research program at IND. Imaging research at IND focuses on functional imaging technology using Positron Emission Tomography (PET) and Single Photon Emission Computerized Tomography (SPECT) imaging.  Using specific radioactively labeled molecules as tags or markers, in conjunction with PET or SPECT imaging offers the opportunity to view the neurochemical activity of the brain.  Functional imaging with PET and SPECT imaging allows us to understand activity in the brain and subtle changes that may occur in early Alzheimer disease, Parkinson disease and other neurodegenerative conditions.


The primary goals of the PET and SPECT imaging studies at IND are:

  • Improving the accuracy of diagnosis of neurodegenerative conditions (Alzheimer disease, Parkinson disease and other neurologic conditions)
  • Enable an earlier diagnosis of neurologic conditions
  • Evaluate severity of disease and monitor disease progression
  • Evaluate the effect of potential disease modifying medications
  • Identify the neurochemical changes occurring with neurodegeneration leading to the development of targets for new, more effective medications


Imaging in Parkinson Disease
Over the past decade researchers at IND have developed and utilized dopamine transporter imaging in several studies to evaluate the diagnosis and monitor progression of Parkinson disease. In our studies, dopamine transporter imaging SPECT discriminated between individuals with Parkinson disease and healthy subjects with a sensitivity of about 98%.

Read More


Imaging in Alzheimer Disease
A major advancement in Alzheimer disease research has been the development of amyloid imaging. It is well recognized that individuals with Alzheimer disease have an accumulation of a protein called amyloid in the brain. Several therapies aimed at slowing the progression of Alzheimer disease by reducing amyloid deposition are being testing in clinical trials. Imaging to detect amyloid in the brain is available in research settings and provides information that is used in conjunction with clinical evaluations. Amyloid imaging may be useful in clarifying a diagnosis of Alzheimer disease and differentiating this from other forms of dementia. 

Read More

  • Home
  • Contact Us
  • Donate
  • Privacy Policy
  • FCOI Policy

Institute for Neurodegenerative Disorders

60 Temple Street, Suite 8B, New Haven, Connecticut 06510, United States

Copyright © 2022 IND - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept